Praktikertjänst-backed Aprea Therapeutics has filed for a $68.3m initial public offering that will fund the clinical progress of its cancer drug candidates.

Aprea Therapeutics, a US-based cancer drug developer backed by healthcare provider Praktikertj√§nst, has filed to raise up to $68.3m in an initial public offering on the Nasdaq Global Select Market. Founded in Sweden in 2003, Aprea is working on cancer treatments intended to reactivate the mutant p53 tumour suppressor protein, which helps prevent the formation…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.